Is Tatva Chintan Pharma Chem Ltd (TATVA) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Tatva Chintan Pharma Chem Ltd is a average quality company .

Is Tatva Chintan Pharma Chem Ltd (TATVA) undervalued or overvalued?

The key valuation ratios of Tatva Chintan Pharma Chem Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Tatva Chintan Pharma Chem Ltd (TATVA) share price return in the past 10 years?

Data is not available for this company

Is Tatva Chintan Pharma Chem Ltd (TATVA) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Tatva Chintan Pharma Chem Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Tatva Chintan Pharma Chem Ltd (TATVA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Tatva Chintan Pharma Chem Ltd (TATVA) on 17-Apr-2026 16:59:59 at 16:59 is 1275.10.

What is the P/E ratio of Tatva Chintan Pharma Chem?

The latest standalone P/E ratio of Tatva Chintan Pharma Chem as of 17-Apr-2026 is 95.74.

What is the P/B ratio of Tatva Chintan Pharma Chem Ltd (TATVA)?

The latest standalone P/B ratio of Tatva Chintan Pharma Chem Ltd (TATVA) as of 17-Apr-2026 is 3.98.

What is the 52-week high and low of Tatva Chintan Pharma Chem Ltd (TATVA)?

The 52-week high of Tatva Chintan Pharma Chem Ltd (TATVA) is Rs. 1603.60 and the 52-week low is Rs. 674.00.

Tatva Chintan Pharma Chem Ltd (TATVA) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Tatva Chintan Pharma Chem Ltd (TATVA)
Brand: Tatva Chintan Pharma Chem

Key Metrics

Market Cap

₹2,983 Cr.

P/E Ratio

95.74

Price to Book (P/B)

3.98

Price to Sales (P/S)

6.33

EV/EBITDA

40.22

Return on Capital Employed (ROCE)

0.26%

Current Price

₹1,275.1

Return on Equity (ROE)

0.05%

Return on Assets (ROA)

0.04%

Operating Profit Margin

7.1%

Net Profit Margin

0.09%

Gross Profit Margin

7.7%

Book Value per Share

₹320.2

Sales Growth (YoY)

-3.24%

Sales Growth (3 Years)

-5.03%

Operating Profit Growth (1 Year)

-61.18%

Operating Profit Growth (3 Years)

-37.4%

Net Profit Growth (1 Year)

-98.88%

52-Week Low / High

₹674 / 1,604

Net Profit Growth (3 Years)

-84.95%

Dividend Yield

0.15%

Promoter Holding

72.02%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Tatva Chintan Pharma Chem Ltd?

Tatva Chintan Pharma Chem Ltd revenue growth is -3.2% for FY-2025 , which is below its 5 year CAGR of 7.6% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Tatva Chintan Pharma Chem Ltd?

Promoters hold 72.02% of the Tatva Chintan Pharma Chem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Tatva Chintan Pharma Chem Ltd vs industry peers?

Tatva Chintan Pharma Chem Ltd revenue CAGR is 7.62% , compared to the industry median CAGR of 7.7% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does Tatva Chintan Pharma Chem Ltd belong to?

Tatva Chintan Pharma Chem Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Chemicals segment.

Q.1 Stock return of Tatva Chintan Pharma Chem Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of -8.04% based on the current price.

DeciZen - make an informed investing decision on Tatva Chintan Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Tatva Chintan Pharma Chem stock performance

Key Ratios

Is Tatva Chintan Pharma Chem Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	27.4%	39%	20.4%	22.2%	26.8%	27.9%	25.8%	7.5%	6.9%	0.3%	-
Value Creation Index ⓘ	1.0	1.8	0.5	0.6	0.9	1.0	0.8	-0.5	-0.5	-1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	89.9	109	129	203	254	291	428	403	379	366	471
Sales YoY Gr.	-	21%	19%	56.8%	25.1%	14.7%	46.9%	-5.8%	-6%	-3.2%	-
Adj EPS ⓘ	3.6	8	5.1	10.3	17.7	24.1	41.6	20.2	11.5	-0.6	13.3
YoY Gr.	-	120.9%	-36.4%	101.2%	72.8%	35.7%	72.8%	-51.4%	-43.4%	-105.2%	-
BVPS (₹) ⓘ	16.1	24.7	30.2	39.6	57	80.6	211.5	227.7	310.3	308.4	320.2
Adj Net Profit ⓘ	7.3	16.1	10.3	20.6	35.6	48.3	92.1	44.8	26.8	-1.4	31
Cash Flow from Ops. ⓘ	8.7	24.3	12.9	7.9	24.6	18.9	19.8	23.7	103	23.9	-
Debt/CF from Ops. ⓘ	2.4	1.9	4.4	9.8	3.7	4.8	6.1	7.2	0.1	1.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	16.9%	7.6%	-5%	-3.2%
Adj EPS ⓘ	-181.7%	-150.6%	-124.2%	-105.2%
BVPSⓘ	38.8%	40.2%	13.4%	-0.6%
Share Price	-	-	-8.5%	76.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	25.4	39.3	18.6	29.4	36.7	35	29.2	9.2	4.4	-0.2	4.2
Op. Profit Mgn % ⓘ	16.5	23.7	15.9	17.1	21.1	22.5	24.8	14.3	17.7	7.1	15
Net Profit Mgn % ⓘ	8.1	14.8	7.9	10.2	14	16.6	21.5	11.1	7.1	-0.4	6.6
Debt to Equity ⓘ	0.7	0.9	0.9	1	0.8	0.6	0.3	0.3	0	0.1	-
Working Cap Days ⓘ	178	175	189	152	156	190	199	251	256	247	110
Cash Conv. Cycle ⓘ	47	54	76	72	85	106	117	167	175	165	56

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	13.3	14
TTM Sales (₹ Cr.)	471	480
BVPS (₹) ⓘ	320.2	329
Reserves (₹ Cr.) ⓘ	726	746
P/BV ⓘ	3.98	3.88
PE ⓘ	95.74	91.04

From the Market
52 Week Low / High (₹)	674.00 / 1603.60
All Time Low / High (₹)	610.00 / 2975.55
Market Cap (₹ Cr.)	2,983
Equity (₹ Cr.)	23.4
Face Value (₹)	10
Industry PE ⓘ	45.3

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Tatva Chintan Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	90	109	129	203	254	291	428	403	379	366
Operating Expenses ⓘ +	75	83	109	170	201	226	322	348	312	340
Manufacturing Costs	5	14	15	20	33	36	65	54	67	65
Material Costs	48	52	68	115	130	148	196	222	168	198
Employee Cost	7	6	10	16	21	24	31	41	55	53
Other Costs ⓘ	15	11	16	18	18	17	30	30	22	24
Operating Profit ⓘ	15	26	21	33	53	65	106	55	67	26
Operating Profit Margin (%)	16.5%	23.7%	15.9%	16.4%	20.8%	22.5%	24.8%	13.6%	17.7%	7.1%
Other Income ⓘ +	1	5	5	0	1	5	11	6	8	4
Exceptional Items ⓘ	0	0	0	1	0	0	0	-4	0	0
Interest ⓘ	2	2	3	4	4	4	5	9	7	1
Depreciation ⓘ	2	2	4	4	5	7	8	10	26	28
Profit Before Tax ⓘ	12	27	18	26	44	59	103	39	42	0
Tax ⓘ	4	10	6	6	9	8	7	-2	13	0
Profit After Tax	7	17	12	20	35	51	96	40	29	0
PAT Margin (%)	8.3%	15.9%	9.2%	10.0%	13.8%	17.6%	22.4%	10.0%	7.8%	0.1%
Adjusted EPS (₹)	3.7	8.6	5.9	10.1	17.4	25.6	43.3	18.3	12.6	0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	20%	5%	11%	16%	715%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	32	50	61	80	114	162	469	505	726	721
Share Capital ⓘ	8	8	8	8	8	20	22	22	23	23
Reserves ⓘ	24	41	53	72	106	142	447	483	702	698
Debt +	21	46	56	71	79	76	106	160	11	36
Long Term Debt	4	17	20	32	39	27	13	4	1	0
Short Term Debt	17	29	36	40	40	49	92	156	10	36
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	15	18	24	22	31	47	44	32	44	32
Others Liabilities ⓘ	3	9	5	14	20	35	49	44	22	21
Total Liabilities ⓘ	71	123	146	187	245	320	667	740	803	811
Fixed Assets
Net Fixed Assets ⓘ +	14	13	56	67	111	120	160	196	427	529
Gross Block	22	22	70	73	122	139	186	232	488	617
Accumulated Depreciation	8	10	13	7	11	18	27	36	61	89
CWIP ⓘ	5	27	10	6	5	10	51	231	77	24
Investments ⓘ	1	1	2	1	1	1	1	1	11	1
Inventories	18	20	24	31	59	68	161	151	144	123
Trade Receivables	20	29	36	45	51	90	62	90	68	76
Cash Equivalents	4	18	8	16	10	4	175	39	37	12
Others Assets ⓘ	10	15	10	23	9	27	59	33	40	46
Total Assets ⓘ	71	123	146	187	245	320	667	740	803	811

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	9	24	13	8	25	19	20	24	103	24
PBT ⓘ	12	27	18	26	44	59	103	39	42	0
Adjustment ⓘ	3	2	-0	7	8	7	10	16	28	28
Changes in Working Capital ⓘ	-1	6	0	-20	-20	-38	-75	-23	39	-0
Tax Paid ⓘ	-4	-10	-5	-6	-7	-10	-18	-8	-6	-4
Cash Flow From Investing Activity ⓘ +	-8	-25	-24	-17	-40	-21	-197	-101	-121	-65
Capex	-7	-25	-24	-10	-48	-21	-89	-203	-128	-76
Net Investments	0	0	0	-7	7	0	-112	97	5	10
Others ⓘ	-1	1	-0	0	1	0	5	5	3	0
Cash Flow From Financing Activity ⓘ +	1	15	1	17	10	-5	235	38	31	17
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	211	0	197	0
Net Proceeds from Borrowing ⓘ	0	0	0	13	13	-9	-13	-13	-9	-3
Interest Paid ⓘ	0	-0	-3	-4	-4	-4	-5	-8	-7	-1
Dividend Paid ⓘ	0	0	0	0	0	-4	0	-4	-5	-5
Others ⓘ	1	15	4	8	1	13	42	64	-146	26
Net Cash Flow ⓘ	1	15	-10	8	-6	-6	58	-40	13	-25

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	25.86	42.25	21.61	28.76	36.03	37.16	30.43	8.31	4.77	0.05
ROCE (%)	27.42	38.98	20.43	22.19	26.78	27.88	25.79	7.49	6.91	0.26
Asset Turnover Ratio	1.43	1.2	0.96	1.22	1.17	1.03	0.87	0.57	0.49	0.45
PAT to CFO Conversion(x)	1.29	1.41	1.08	0.4	0.71	0.37	0.21	0.6	3.55	N/A
Working Capital Days
Receivable Days	83	76	91	72	69	88	65	68	76	72
Inventory Days	58	61	63	50	65	80	98	141	142	133
Payable Days	131	118	114	73	75	96	85	62	82	71

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Tatva Chintan Pharma Chem Ltd FAQs

The current trading price of Tatva Chintan Pharma on 17-Apr-2026 16:59 is ₹1,275.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Tatva Chintan Pharma stood at ₹2,982.7 Cr

The latest P/E ratio of Tatva Chintan Pharma as of 16-Apr-2026 is 95.74.

The latest P/B ratio of Tatva Chintan Pharma as of 16-Apr-2026 is 3.98.

The 52-week high of Tatva Chintan Pharma is ₹1,603.6 and the 52-week low is ₹674.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tatva Chintan Pharma is ₹471 ( Cr.) .

About Tatva Chintan Pharma Chem Ltd

The company is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes. For instance, its SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.

The company continuously strive to improve its processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of its products, it serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from company’s customers in India, it also export its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.

Business area of the company

The company is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.

Awards, accreditations or recognitions

2006: Received ISO 9001:2015 certification for manufacturing facility at Ankleshwar.
2015: Appreciation certificate from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for Company’s contribution to the revenue and voluntary compliance with tax laws.
2016: Accorded the status of a two star export house from the Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India.
2017: Received ISO 14001:2015 and BS OHSAS 18001:2007 certification for our manufacturing facility at Ankleshwar.
2018: Received ISO 9001: 2015 certification for manufacturing facilities at Ankleshwar and Dahej.
2018: Received ISO 14001: 2015 and BS OHSAS 18001:2007 certification for manufacturing facility at Dahej.
2019: R&D facility recognized by the Department of Scientific and Industrial Research, Government of India for the purpose of availing customs duty exemption.
2020: Received ISO 14001:2015 and 45001:2018 certification for manufacturing facility at Ankleshwar.

Major events and milestones

1996: Incorporation of the company.
2004: Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at our Ankleshwar Manufacturing Facility.
2007: Expansion of manufacturing capacity at Ankleshwar Manufacturing Facility.
2011: Commenced commercial manufacturing of SDAs.
2013: Attained turnover of Rs 500.00 million.
2015: Attained turnover of Rs 1 billion.
2015: Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of Company.
2015: Set up warehousing facility in Netherlands.
2017: Set up Dahej Manufacturing Facility.
2018: Set up R&D facility in Vadodara.
2019: Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of Company.
2020: Completion of ‘Together for Sustainability’ audit.
2020: Conversion of Ankleshwar Manufacturing Facility to a ‘zero liquid effluent discharge facility’.
2020: Attained total revenue of Rs 2 billion.
2020: Increase in manufacturing capacity at our Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of our Company from 160 KL and 10 Assembly Lines to 280 KL and 13 Assembly Lines.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Tatva Chintan Pharma Chem Ltd (TATVA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Tatva Chintan Pharma Share Price